Updated:
TG Therapeutics
TG Therapeutics, led by Michael S. Weiss, is the biotech that brought Briumvi, an anti-CD20 MS therapy, to market in 2023.
TG Therapeutics
TG Therapeutics launched in 2012 under the direction of Executive Chairman and CEO Michael S. Weiss, a veteran biotech executive who previously built and sold Keryx Biopharmaceuticals. The company is not a family office or fund — it is a fully integrated commercial-stage biopharmaceutical company headquartered in Morrisville, North Carolina. Its core identity rests on developing novel treatments for B-cell diseases. The company took an unconventional path by advancing an anti-CD20 monoclonal antibody, ublituximab, through pivotal trials while simultaneously holding a portfolio of PI3K-delta and CK1-epsilon inhibitors. The firm's strategy focuses wholly on acquiring, developing, and commercializing therapeutic candidates for hematologic malignancies and autoimmune diseases. Its primary asset, Briumvi (ublituximab-xiiy), received FDA approval in December 2022 for relapsing forms of multiple sclerosis. TG Therapeutics launched the drug commercially in early 2023, competing directly with established anti-CD20 therapies like Ocrevus and Kesimpta. The company's pipeline also includes TG-1701, a BTK inhibitor, and TG-1801, an anti-CD47/CD19 bispecific antibody, under clinical investigation for non-Hodgkin's lymphoma. Its geographic footprint concentrates in the United States, where it manages its own specialty pharmaceutical sales force, with commercialization agreements covering other territories. TG Therapeutics operates from its single headquarters in North Carolina and has publicly shifted its resource allocation toward the Briumvi commercial launch following the voluntary withdrawal of its PI3K-delta inhibitor, Ukoniq, from oncology markets in 2022. This decision followed an FDA clinical hold and a subsequent strategic pivot that refocused the entire enterprise on the multiple sclerosis market. The company remains without a large-cap pharmaceutical partner for its lead asset, keeping US commercialization rights fully in-house — an uncommon structural choice that concentrates operational complexity but preserves margin. Structurally, TG Therapeutics is a publicly traded C-corporation dependent on drug sales and secondary equity offerings rather than the limited-partner commitments typical of a family office or investment fund model. The firm's governance sits under a board led by Weiss, who retains significant executive authority over both clinical pipeline prioritization and commercial execution. There is no intergenerational wealth transfer story, no foundation structure managing donor-advised funds — this is a biotechnology company whose future rests on delivering quarterly Briumvi prescription growth.
General information
Firm type
Asset Manager
Year founded
2012
AUM
Undisclosed
Location
Region
North America
Country
United States
City
Morrisville
Corporate office
Morrisville, NC, United States
Principals
Michael S. Weiss
Executive Chairman and CEO
Sean A. Power
Chief Financial Officer
Sector focus
Frequently asked questions
Is TG Therapeutics a single family office or a traditional investment fund?
TG Therapeutics is neither — it is a publicly traded commercial-stage biotechnology company (NASDAQ: TGTX). The firm discovers, develops, and markets proprietary drug therapies rather than managing family wealth or third-party capital in pooled investment vehicles. Its founder, Michael Weiss, serves as CEO and Chairman, but the company's asset base reflects a drug development pipeline rather than a discretionary AUM pool.
What generates revenue for TG Therapeutics, and who manages the drug's commercial rollout?
Revenue comes from US net sales of Briumvi (ublituximab-xiiy), an anti-CD20 monoclonal antibody approved for relapsing multiple sclerosis in December 2022. Michael Weiss leads the overall commercial strategy, supported by an in-house specialty sales force responsible for engaging neurologists across the United States. TG Therapeutics declined to partner Briumvi commercially in the US, retaining full distribution rights.
Was the pivot away from oncology a set-back or a deliberate strategic necessity for the firm?
It was a forced necessity. The firm voluntarily withdrew its PI3K-delta inhibitor, Ukoniq, from the market in 2022 and terminated related oncology clinical trials after the FDA placed a clinical hold over safety concerns. Management rapidly redirected all available resources toward the Briumvi launch, effectively repositioning TG Therapeutics from a dual-focus oncology-and-autoimmune enterprise into an MS-focused commercial biotech.
Who executes investment or capital-allocation decisions at TG Therapeutics?
Capital allocation is an executive-level function led by CEO Michael Weiss and CFO Sean Power. As a publicly traded biotech, decisions center on clinical-trial funding, manufacturing scale-up for Briumvi, and commercial infrastructure rather than portfolio allocation across external assets or funds. The company relies on periodic equity offerings for financing — unlike a family office or fund, it does not make financial investments in unrelated third-party GPs.
Does TG Therapeutics maintain philanthropic structures or family-office adjacent vehicles?
The company does not operate a donor-advised fund, foundation, or family-office adjacent entity. All reported assets and operations sit under the publicly traded corporate umbrella. Philanthropic activity typically occurs through standard corporate channels — patient-access programs for Briumvi — rather than via a separate wealth-management or foundation structure common to family offices.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on family offices?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: